TALON phase IIIb study: 64 week results of brolucizumab versus aflibercept using treat-and-extend for neovascular age-related macular degeneration
The Week 64 results in TALON reaffirmed those reported at Week 32, demonstrating extended treatment intervals and an overall favourable benefit/risk profile for brolucizumab in patients with nAMD.
Authors
- Mark C. Gillies (ORCID: https://orcid.org/0000-0001-8580-0274)
- Frank Gerhard Holz (ORCID: https://orcid.org/0000-0001-8019-9272)
- Peter J. Kertes (ORCID: https://orcid.org/0000-0002-0348-5096)
- Peter K. Kaiser (ORCID: https://orcid.org/0000-0001-5126-045X)
- Tina Maio‐Twofoot
- David A. Lawrence (ORCID: https://orcid.org/0000-0002-8940-9640)
- Carl D. Regillo (ORCID: https://orcid.org/0000-0001-8260-9925)
Institutions
- Novartis (Switzerland) (CH)
- Cleveland Clinic (US)
- Sunnybrook Health Science Centre (CA)
- University of Bonn (DE)
- Thomas Jefferson University (US)
- Health Sciences Centre (CA)
- Sydney Hospital (AU)
- Cleveland Eye Clinic (US)
- Wills Eye Hospital (US)
Publication Details
- Journal
- Eye
- Published
- 2025-12-18
- DOI
- https://doi.org/10.1038/s41433-025-04161-x
- Citations
- 1
- Primary Topic
- Retinal Diseases and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 1.71
Funders
- Novartis Pharma